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Abstract
Background: Diabetic cardiomyopathy (CMP) is a common and disabling disease in diabetic patients, however no
effective treatments have been developed. Although granulocyte-colony stimulating factor (G-CSF) improves heart
function in myocardial infarction, its effect on non-ischemic CMP such as diabetic CMP is unknown. In the present
study, we investigated the effects of G-CSF on diabetic CMP in a rat model of type II diabetes.
Methods: Twenty 7-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF: a rat model of diabetes) rats and
10 male Long-Evans Tokushima Otsuka (LETO: normal controls) rats were used. All of the LETO and 8 OLETF rats
were fed on tap water while the rest were fed on sucrose-containing water. After 10 weeks, saline or recombinant
human G-CSF (100 μg/kg/day) was injected intraperitoneally for 5 days. Blood levels of glucose, total cholesterol
and triglyceride, and Doppler echocardiograms for diastolic dysfunction were obtained just before and 4 weeks
after the saline or G-CSF treatment. Light microscopy, electron microscopy (EM) and immunohistochemistry for
transforming growth factor-b were employed to examine myocardial histology 4 weeks after the saline or G-CSF
treatment.
Results: Diastolic dysfunction developed at 17 weeks (before the saline or G-CSF treatment) in the OLETF rats
whether or not they were fed sucrose water, but were more severe in those fed sucrose water. Four weeks after
saline or G-CSF treatment, diastolic function had recovered in the G-CSF-treated group regardless of sucrose water
feeding, and perivascular and/or interstitial fibrosis in the G-CSF-treated group had decreased significantly. TGF-b
immunoreactivity in the interstitial and perivascular tissue was also reduced in the G-CSF-treated group, and EM
studies revealed less severe disruption of myofilaments and mitochondrial cristae, and decreased collagen
deposition.
Conclusions: G-CSF can ameliorate cardiac diastolic dysfunction and morphological damage, especially fibrosis of
the myocardium, in OLETF rats with diabetic CMP.
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Introduction
Diabetic cardiomyopathy (CMP) is defined as cardiac
failure when possible etiologies such as alcohol, hyper-
tension, and coronary and structural heart disease have
been excluded in diabetic patients [1]. In a previous
study using type II diabetes mellitus (DM) rats model,
diabetic CMP was characterized functionally by the pre-
sence of left ventricular diastolic dysfunction, and histo-
logically by interstitial fibrosis and collagen
accumulation [2]. Diabetic CMP has been reported in
30-75% of diabetic patients, and is an important cause
of heart failure [3-7]. The worldwide prevalence of dia-
betes has been estimated to increase from 2.8% in 2000
to 4.4% in 2030, this could lead to an increase of dia-
betic CMP [8]. Although coronary artery diseases are
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the main cause of heart failure and deteriorating func-
tion, the high incidence of diabetic CMP indicates that
diabetes itself is an important factor in myocardial
damage. There are currently no clearly established treat-
ments for diabetic CMP [9,10]. Conventional therapeutic
practice, such as strict control of blood glucose level and
avoidance of traditional risk factors, is often effective,
but does not completely prevent cardiac complications
[11-13]. Therefore, there is a great need to develop
effective treatments for diabetic CMP.
Recent studies have shown that granulocyte-colony
stimulating factor (G-CSF) reduces the size of infarcts,
induces myocardial regeneration and is responsible for
recovery of heart function in myocardial infarction (MI)
[14-17]. Based on these reports, we hypothesized that
G-CSF might also have beneficial effects on non-
ischemic CMP, such as diabetic CMP. Therefore, in the
present study, we investigated the functional and histo-
logical effects of G-CSF on diabetic cardiomyopathy in
Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
Methods
Subjects
This work was performed in compliance with the
ARRIVE guidelines on animal research [18]. We used as
experimental subjects twenty male Otsuka Long-Evans
Tokushima Fatty (OLETF) rats; these rats were
developed as spontaneous long-term hyperglycemic rats
with type II DM [19]. Ten male Long-Evans Tokushima
Otsuka (LETO) rats, which were developed from the
same colony by selective mating but do not develop
DM, were used as control animals. All the rats were
kept in the specific pathogen-free facility of the Hanyang
University Medical School Animal Experiment Center at
controlled temperature (23 ± 2°C) and humidity (55 ±
5%) with a 12-hour artificial light and dark cycle. All
rats care and experimental procedures were performed
according to the guidelines of Hanyang University for
Experiments in Animals, and all protocols were
approved by the Hanyang University Institutional
Review Board.
Experimental protocols
The numbers of rats in each group of LETO and
OLETF rats and a schema of the experimental protocol
are given in Figure 1. This experiment started at rat age
of 7 weeks. The rats were given free access to standard
laboratory rat chow, all of the LETO (LETO (-)) and 8
randomly selected OLETF rats were given free access to
tap water (OLETF (-)), and other 12 OLETF rats were
given free access to water containing 30% sucrose
(OLETF (+)). At rat age of 17 weeks (after 10 weeks),
each OLETF rat groups was divided randomly into two
groups, which were injected, respectively, with saline or
Figure 1 Brief experimental protocol. LETO; Long-Evans Tokushima Otsuka rat, OLETF; Otsuka Long-Evans Tokushima Fatty rat, G-CSF;
granulocyte-colony stimulating factor, BW; body weight, BP; blood pressure, HR; Heart rate. LETO (-); LETO rats fed on tap water, OLETF (-); OLETF
rats fed on tap water, OLETF (+); OLETF rats fed on sucrose contained water, OLETF (-/-); OLETF rats fed on tap water and treated with saline,
OLETF (-/+); OLETF rats fed on tap water and treated with G-CSF, OLETF (+/-); OLETF rats fed on sucrose water and treated with saline, OLETF
(+/+); OLETF rats fed on sucrose water and treated with G-CSF. * Rats expired during blood pressure measurement
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recombinant human G-CSF (100 μg/kg/day; Dong-A
Pharmacological, Seoul, Korea) intraperitoneally for 5
days. Thus there were eventually 5 groups of rats: LETO
rats fed on tap water (LETO (-)), OLETF rats fed on tap
water and treated with saline (OLETF (-/-)), OLETF rats
fed on tap water and treated with G-CSF (OLETF (-/+)),
OLETF rats fed on sucrose water and treated with saline
(OLETF (+/-)) and OLETF rats fed on sucrose water
and treated with G-CSF (OLETF (+/+)).
Body weight, fasting blood glucose (FBG), total choles-
terol (TC) and triglyceride (TG), heart rate (HR), systo-
lic blood pressure (SBP) were measured, and Doppler
echocardiography performed, at two times: first at the
age of 17 weeks (just before treated) and second at the
age of 22 weeks (4 weeks after the 5-day intraperitoneal
saline or G-CSF injection). After the rats were killed,
myocardial histology was examined with light micro-
scopy, immunohistochemistry for transforming growth
factor (TGF)-b and electron microscopy (EM).
SBP was measured by the tail-cuff method (Sphygmo-
manometer PS-100 Rick, Riken Kaihatsu). Blood tests
were measured in tail capillary blood after 8 hours of
fasting.
Echocardiography
Each rat was anesthetized with 50 mg/kg ketamine and 5.8
mg/kg xylazine HCl, and the left side of the chest was
shaved to gain a clear image. Doppler echocardiography
was performed by a single sonographer. Serial echocardio-
graphic examinations (Philips iE33, Philips Medical System
with an S8-3 probe) were performed with the rats in the
left lateral decubitus position. The transmitral flow velocity
profile was determined by positioning a sample volume at
the tip of the mitral valve on the apical four chamber view.
The Doppler beam was set with < 15° of the incident angle
to flow direction identified on color Doppler image. Angle
correction was performed by a semiautomated system
installed in the machine. The peak velocity (E), deceleration
time (DT) of the early diastolic filling wave and early mitral
annulus velocity (E’) were measured. DT was obtained by
extrapolating the initial slope of early diastolic filling wave
deceleration to the baseline. E’ was measured at the septal
portion of the mitral annulus in an apical four chamber
view, using tissue Doppler technique with a Nyquist limit of
15 cm/s. The transmitral inflow pattern was recorded on a
strip chart at 100 mm/s sweep speed with simultaneous 3-
lead electrocardiography for offline analysis. All measure-
ments represented the mean of 5 consecutive cardiac cycles,
and heart rate was calculated on the basis of the strip chart
of Doppler echocardiography.
Euthanasia and Histopathological Methods
Rats were anesthetized with 50 mg/kg ketamine and 5.8
mg/kg xylazine HCl. The hearts were excised and
separated into 2 halves along the anterior longitudinal
middle line. One half of the heart was fixed with forma-
lin solution, embedded in paraffin and cut into sections
4 μm thick for H&E, Masson’s trichrome staining and
immunostaining for the TGF-b receptor (SC-146, Santa
Cruz Biotechnology, dilution 1:100). The other half of
each heart was frozen in liquid nitrogen and stored at
280°C for electron microscopic examination. Interstitial
fibrosis and perivascular fibrosis were measured, using
Image Pro plus 6.0 imaging software (Media Cyber-
netics, Silver Spring, MD) and the results were
expressed as percentages.
Electron microscopy
For electron microscopic examination, a portion of the
left ventricle was cut into 1 mm fragments and fixed in
2.5% glutaraldehyde (0.2 M cacodylate buffer, pH 7.4)
for 4 hours and in 1% buffered sodium tetroxide for 1
hour, and then embedded in Epon 812. Survey sections
were cut at 1 μm and stained with toluidine blue. Ultra-
thin sections were cut in from this block and studied
under a Hitachi H-7600S electron microscope at 80 KV.
Statistical Analysis
All values are means ± standard deviation (SD). Statisti-
cal differences were determined with Statistical Package
for the Social Sciences (SPSS) 18.0 software (SPSS Inc.,
Chicago, IL, USA). Data were analyzed by t-tests (for
single comparisons) or one-way ANOVA (for multiple
comparisons), and Post Hoc multiple comparisons were
made with Tukey’s test (equal variances assumed) or
Tamhane’s T2 test (equal variances not assumed). p
values of less than 0.05 were considered significant.
Results
1) Establishment of diabetic cardiomyopathy
Table 1 presents baseline data on the three groups of
rats at 17 weeks, before treatment with G-CSF. Body
weight and blood level of TG were significantly higher
in the OLETF groups than the LETO (-). However,
blood levels of FBG, and TC did not differ between the
OLETF and LETO (-) groups. Also no significant differ-
ences in blood levels of FBG, TC and TG were observed
between the two OLETF groups.
E and E’ were lower and E/E’ was higher in the two
OLETF groups than in the LETO (-) rats, showing that
diastolic dysfunction had developed in the OLETF rats.
Moreover the OLETF (+) rats had lower E’ and higher
E/E’ than the OLETF (-) rats; thus diastolic dysfunction
was more pronounced in the sucrose-fed OLETF rats.
In that, diabetic CMP models using OLETF rats were
comparatively well made when compared with age-
matched LETO rats group, using diastolic function para-
meters by Doppler echocardiography.
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2) G-CSF improves cardiac diastolic function
Doppler echocardiography was performed four weeks
after the series of intraperitoneal injections of G-CSF
or normal saline. In the tap water groups, E’ showed
a higher trend (p = 0.062) and E/E’ was lower (p <
0.05) in the G-CSF treated (OLETF (-/+)) rats than
the saline-treated (OLETF (-/-)) rats. This shows
that G-CSF had a protective effect on diastolic func-
tion. Furthermore, there were no significant differ-
ences of E, E ’ and E/E ’ between OLETF (-/+) and
LETO (-), indicating that G-CSF increased diastolic
function to a level similar to that in the control rats.
(Table 2)
A more clear-cut set of findings was obtained in the
two groups of OLETF rats fed on sucrose-containing
water. The differences between the OLETF rats injected
with G-CSF (OLETF (+/+)) and those injected with nor-
mal saline (OLETF (+/-)) were more prominent, with E’
higher and E/E’ lower in the OLETF (+/+) compared
with the OLETF (+/-) rats. Moreover, E’ and E/E’ did
not differ between the OLETF (+/+) and LETO (-) rats,
indicating that G-CSF treatment also improved diastolic
function to a level comparable with that in normal rats.
(Table 3)
The changes in E, E’ and E/E’ of OLETF rats fed on
sucrose-containing water and then injected with saline
of G-CSF are shown in Table 4 and Figure 2. E ’
increased significantly and E/E’ was maintained in the
OLETF (+/+), while E’ decreased and E/E’ increased
significantly in the OLETF (+/-). In those treated with
saline (OLETF (+/-)), most of the subjects showed a
decline in E’ and a rise in E/E’. In contrast, in those
treated with G-CSF (OLETF (+/+)), an increase in E’
and a decrease in E/E’ was seen in most of the sub-
jects. These results mean that diastolic function was
preserved or even improved in the rats treated with G-
CSF.
Table 2 Data of LETO rats and OLETF rats fed on tap
water at the time of 22 weeks old (4 weeks after G-CSF
or saline treatment)
LETO (-)
(n = 8)
OLETF (-/-)
(n = 4)
OLETF (-/+)
(n = 2)
p
BW (g) 444.0 ± 15.2 600.2 ± 31.2* 537.5 ± 95.5** < 0.001
FBG
(mg/dl)
210.8 ± 46.6 364.0 ± 120.0** 281.0 ± 89.1 0.025
TC
(mg/dl)
55.4 ± 6.9 61.5 ± 7.6 61.0 ± 12.7 0.397
TG (mg/dl) 45.9 ± 12.5 151.0 ± 62.0* 162.0 ± 46.7* 0.001
HR (bpm) 292.9 ± 18.1 283.5 ± 28.3 291.0 ± 24.0 0.785
E (cm/sec) 79.5 ± 4.2 73.6 ± 2.2 75.2 ± 0.4 0.051
E’ (cm/sec) 7.1 ± 0.5 5.7 ± 0.3* 6.7 ± 0.4 0.001
E/E’ 11.2 ± 0.6 12.9 ± 0.7* 11.3 ± 0.7‡ 0.004
DT (msec) 76.4 ± 5.5 68.5 ± 12.8 73.5 ± 0.7 0.311
BP
(mmHg)
160.0 ± 14.1 167.2 ± 10.1 167.4 ± 34.8 0.950
Values are mean ± SD. *p < 0.01 and **p < 0.05 versus LETO (-). †p < 0.01
and ‡p < 0.05 versus OLETF (-/-).
LETO; Long-Evans Tokushima Otsuka rat, OLETF; Otsuka Long-Evans
Tokushima Fatty rat, G-CSF; granulocyte-colony stimulating factor, BW; body
weight, FBG; fasting blood glucose, TC; total cholesterol, TG; triglyceride, HR;
Heart rate, E; peak velocity of the early diastolic filling wave, E’; early mitral
annulus velocity, DT; deceleration time BP; blood pressure,
LETO (-); LETO rats fed on tap water,
OLETF (-/-); OLETF rats fed on tap water and treated with saline,
OLETF (-/+); OLETF rats fed on tap water and treated with G-CSF
Table 3 Data of LETO rats and OLETF rats fed on sucrose
contained water at the time of 22 weeks old (4 weeks
after G-CSF or saline treatment)
LETO (-)
(n = 8)
OLETF (+/-)
(n = 6)
OLETF (+/+)
(n = 6)
p
BW (g) 444.0 ± 15.2 624.0 ± 23.8* 598.7 ± 50.8* < 0.001
FBG (mg/dl) 210.8 ± 46.6 367.3 ± 47.9* 314.0 ± 56.2* < 0.001
TC (mg/dl) 55.4 ± 6.9 58.5 ± 9.7 54.2 ± 16.5 0.790
TG (mg/dl) 45.9 ± 12.5 116.3 ± 16.4* 128.2 ± 55.9** < 0.001
HR (bpm) 292.9 ± 18.1 291.7 ± 35.5 289.5 ± 18.6 0.968
E (cm/sec) 79.5 ± 4.2 70.1 ± 1.4* 73.9 ± 3.3** 0.001
E’ (cm/sec) 7.1 ± 0.5 4.7 ± 0.1* 6.6 ± 0.2† < 0.001
E/E’ 11.2 ± 0.6 15.0 ± 0.7* 11.3 ± 0.8† < 0.001
DT (msec) 76.4 ± 5.5 69.3 ± 7.7 72.0 ± 4.0 0.105
BP (mmHg) 160.0 ± 14.1 166.9 ± 2.0 177.0 ± 21.9 0.587
Values are mean ± SD. *p < 0.01 and **p < 0.05 versus LETO (-). †p < 0.01
and ‡p < 0.05 versus OLETF (+/-).
LETO; Long-Evans Tokushima Otsuka rat, OLETF; Otsuka Long-Evans
Tokushima Fatty rat, G-CSF; granulocyte-colony stimulating factor, BW; body
weight, FBG; fasting blood glucose, TC; total cholesterol, TG; triglyceride, HR;
heart rate, E; peak velocity of the early diastolic filling wave, E’; early mitral
annulus velocity, DT; deceleration time, BP; blood pressure,
LETO (-); LETO rats fed on tap water,
OLETF (+/-); OLETF rats fed on sucrose water and treated with saline,
OLETF (+/+); OLETF rats fed on sucrose water and treated with G-CSF
Table 1 Baseline data before treatment with G-CSF or
saline (at the time of 17 weeks old)
LETO (-)
(n = 8)
OLETF (-)
(n = 7)
OLETF (+)
(n = 12)
p
BW (g) 428 ± 18.8 551.4 ± 44.9* 595.7 ± 37.5*‡ < 0.001
FBG
(mg/dl)
125.4 ± 9.8 148.0 ± 28.5 151.3 ± 34.5 0.129
TC (mg/dl) 71.9 ± 19.8 97.3 ± 25.0** 89.8 ± 15.1 0.045
TG (mg/dl) 46.6 ± 23.4 197.7 ± 91.2** 190.7 ± 41.6* < 0.001
HR (bpm) 312.9 ± 18.7 297.6 ± 24.5 298.8 ± 12.2 0.177
E (cm/sec) 72.8 ± 3.3 66.3 ± 1.7** 65.5 ± 5.4* 0.002
E’ (cm/sec) 9.0 ± 1.4 6.7 ± 0.2* 5.2 ± 0.3*† < 0.001
E/E’ 8.2 ± 1.0 9.8 ± 0.4* 12.5 ± 0.8*† < 0.001
DT (msec) 81.8 ± 12.3 83.6 ± 9.5 86.3 ± 11.4 0.675
Values are mean ± SD. *p < 0.01 and **p < 0.05 versus LETO (-). †p < 0.01
and ‡p < 0.05 versus OLETF (-).
LETO; Long-Evans Tokushima Otsuka rat, OLETF; Otsuka Long-Evans
Tokushima Fatty rat, BW; body weight, FBG; fasting blood glucose TC; total
cholesterol, TG; triglyceride, HR; Heart rate, E; peak velocity of the early
diastolic filling wave, E’; early mitral annulus velocity, DT; deceleration time,
LETO (-); LETO rats fed on tap water, OLETF (-); OLETF rats fed on tap water,
OLETF (+); OLETF rats fed on sucrose contained water
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Figure 2 Changes in diastolic parameters of individual subjects of the OLETF rats fed on sucrose contained water group; OLETF rats
treated with saline (OLETF (+/-)) (left) and OLETF rats treated with G-CSF (OLETF (+/+) (right). E; peak velocity of the early diastolic filling
wave, E’; early mitral annulus velocity, E1, E’1, E/E’1:pre-treatments state, E2, E’2, E/E’2: four weeks after treatments.
Table 4 Changes of echocardiographic data pre- and post-treatment of OLETF rats fed on sucrose contained water
OLETF (+/-) OLETF (+/+)
Pre-
treatment
Post-
treatment
p Pre-
treatment
Post-
treatment
p
E (cm/sec) 68.7 ± 6.1 70.1 ± 1.4 0.611 62.4 ± 1.8 73.9 ± 3.3 0.001
E’ (cm/sec) 5.3 ± 0.3 4.7 ± 0.1 0.006 5.2 ± 0.3 6.6 ± 0.2 0.001
E/E’ 13.0 ± 0.5 15.0 ± 0.7 0.001 12.0 ± 0.6 11.3 ± 0.8 0.224
Values are mean ± SD.
OLETF; Otsuka Long-Evans Tokushima Fatty rat, G-CSF; granulocyte-colony stimulating factor, E; peak velocity of the early diastolic filling wave, E’; early mitral
annulus velocity
OLETF (+/-); OLETF rats fed on sucrose water and treated with saline,
OLETF (+/+); OLETF rats fed on sucrose water and treated with G-CSF
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3) G-CSF prevents histological damage to the
myocardium in the diabetic rats
Masson trichrome staining revealed less perivascular and
interstitial fibrosis in the OLETF rats treated with G-
CSF than in those treated with saline. In the Image-pro
analysis, the extent of fibrosis was greater in the OLETF
groups than in the LETO group, and significantly lower
in the G-CSF- treated group than the saline-treated
group. In subgroup analysis, both groups of OLETF rats
treated with G-CSF displayed less fibrosis than those
treated with saline. (Figure 3)
Similarly only a low level of interstitial immunostain-
ing for TFG-b was observed in the OLETF (-/-) rats,
and a complete absence of staining in the OLETF (-/+)
rats. Likewise, the level of TGF-b immunoreactivity in
interstitial and perivascular tissue was significantly lower
in the OLETF (+/+) rats than in the OLETF (+/-) rats.
(Figure 4)
Electron microscopy revealed more pronounced het-
erogeneous structural alterations in the myocardial tis-
sue of the OLETF (+/-) rats than in that of the OLETF
(+/+) rats. Ultrastructurally the OLETF (+/-) myocar-
dium showed the presence of intracellular edema,
deposition of collagen fibers in the pericapillary region,
swelling and disrupted mitochondrial cristae, and
damaged myofilaments and intracellular junctions, as
well as increased accumulation of lipid droplets and
lysosomes in the cardiac cells, In contrast, collagen
deposition was absent from the OLETF (+/+) myocar-
dium and there were fewer abnormal mitochondria.
Moreover there was less evidence of disruption of the
cristae of enlarged mitochondria, or of damaged myofi-
laments and intracellular junctions. (Figure 5)
Discussion
In the diabetic heart, the functional alterations are
preceded by a variety of structural, molecular and cel-
lular changes, many of which are present in asympto-
matic diabetic individuals and experimental models of
diabetes. Moreover, the undermining of myocardial
and vascular integrity appears to begin during the
pre-diabetic stage [20]. In a recent study, changes in
cardiac heparin sulfate proteoglycan expression and
the diastolic dysfunction, an early sign of diabetic
CMP occurred as parallel events. Although several
pathophysiological mechanisms have been proposed
to explain the diabetic CMP, it remains poorly under-
stood [20,21].
Another study reported that in an MI model, hyper-
glycemia had a beneficial effect on delaying ischemic-
reperfusion injury and left ventricular dysfunction, how-
ever hyperglycemia did not decrease mortality rate [22],
and diabetic CMP is a very important cause of heart
failure [3-7].
In this study we evaluated the functional and histolo-
gical effect of G-CSF on relatively early diabetic CMP.
We observed no substantial differences in blood levels
of FBG, TC and TG between G-CSF-treated and saline-
treated OLETF rats, suggesting that G-CSF does not sig-
nificantly affect glucose and lipid metabolism.
In diabetic CMP, diastolic dysfunction is well on the
way even before symptoms appear in the patient. There-
fore, we evaluated E, E’, DT and E/E’ using Doppler
echocardiography and tissue Doppler to assess the
degree of diastolic dysfunction. We found that diastolic
dysfunction was minimal or completely recovered in
OLETF rats treated with G-CSF.
The beneficial effects of G-CSF were shown in the his-
tologic findings as well. We found that perivascular and
interstitial fibrosis progressed more slowly or even
showed improvement in G-CSF treated OLETF rat
groups. Also, the extent of TGF-b immunoreactivity in
the interstitial and perivascular tissue was significantly
decreased in G-CSF treated OLETF rat groups. EM stu-
dies revealed decreased collagen deposition and lesser
number of abnormal mitochondria, damaged myofila-
ments and intracellular junctions were also noted in G-
CSF treated OLETF rats. Our results indicate that the
protective effects of G-CSF are seen not only in rela-
tively advanced diabetic CMP but also in its early stages.
Although various animal models have been used to
investigate diabetes-related changes in the myocardium
including interstitial fibrosis, cardiomyocyte loss,
impaired energy utilization, small vessel disease and
neuropathy, the pathophysiology of diabetic cardiomyo-
pathy remains to be fully elucidated [10]. The present
study provides the first evidence of the beneficial effects
of G-CSF on diabetic CMP in OLETF rats, an animal
model of non-ischemic CMP. The two major findings of
this study were that G-CSF delayed a progression of dia-
stolic dysfunction, in terms of function, and prevented
interstitial and perivascular fibrosis, in terms of pathol-
ogy. Until now the beneficial effect of G-CSF on the
heart has been mainly studied in the myocardial infarc-
tion model. Although there have been a few studies of
the effect of G-CSF on non-ischemic CMP, studies on
the effect of G-CSF on diabetic CMP are limited [23,24].
G-CSF has various functions such as induction of pro-
liferation, survival and differentiation of hematopoietic
cells and mobilization of bone marrow cells [25-27]. It
has been reported that bone marrow cells can differenti-
ate into cardiomyocytes and vascular cells, thereby con-
tributing to the regeneration of myocardium and to
angiogenesis in ischemic hearts [28,29]. According to
recent reports, G-CSF reduces the size of infarcts,
induces myocardial regeneration and contributes to the
recovery of heart function. To account for the effects of
G-CSF it has been proposed that it promotes the
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Figure 3 The representative sections for Masson trichrome staining OLETF groups.(*200). The perivascular and interstitial fibrosis is
demonstrated as blue color on Masson Trichrome stain. Proportion of fibrosis (bottom) is significantly decreased in G-CSF treated OLETF rat (E, F:
Image Pro analysis). * p < 0.05, ** p < 0.01. A. OLETF (-/-); OLETF rat fed on tap water and treated with saline, B. OLETF (-/+); OLETF rat fed on
tap water and treated with G-CSF, C. OLETF (+/-); OLETF rat fed on sucrose water and treated with saline, D. OLETF (+/+); OLETF rat fed on
sucrose water and treated with G-CSF.
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mobilization of bone marrow stem cells or acts directly
on cardiomyocytes of the injured heart, however the
precise mechanisms of the beneficial effects of G-CSF
are not fully understood [14-17]. The therapeutic effects
of G-CSF have been also described in non-ischemic
dilated cardiomyopathies such as idiopathic dilated
CMP or doxorubicin-induced CMP [23,24].
Harada et al. have discussed the possible molecular
mechanisms of G-CSF action in preventing left ventricu-
lar remodeling after MI. They found that G-CSF acted
directly on a G-CSF receptor expressed on cardiomyo-
cytes and activated the Jak/Stat pathway. G-CSF also
induced antiapoptotic proteins and inhibited apoptotic
death of cardiomyocytes [14]. Baldo MP et al. recently
reported that G-CSF preserved left ventricular function
through early infarct size reduction and the attenuation
of cardiac remodeling after MI via anti-apoptotic protein
upregulation and an early reduction in cardiomyocyte
apoptosis [15]. Minatoguchi et al. hypothesized that G-
CSF accelerate the healing of MI wounds and they
reported that it accelerated absorption of necrotic tis-
sues by increasing macrophage numbers, and reduced
granulation and scar tissue by promoting the expression
of matrix metalloproteinases [16]. Hamamoto et al.
reported that G-CSF promoted the migration of bone
marrow cells to diseased hearts and also directly
enhanced the proliferation of troponin I-positive cardio-
myocytes via G-CSF receptors on the cardiomyocytes
[23]. Although many proposals regarding the mechan-
ism of the protective effects of G-CSF on myocardium
have been reported, the exact mechanism is yet to be
established [14-17].
Figure 4 The representative sections of immunohistochemical staining for TGF-b in non-treated and G-CSF treated OLETF rats. Tissues
expressing TGF-b appeared brown color. (*200). The minimal interstitial staining for TGF-b is found in OLETF (-/-), whereas complete absence in
OLETF (-/+). Similarly, the extent of TGF-b immunoreactivity in the interstitial and perivascular tissue is significantly decreased in OLETF (+/+)
compared with OLETF (+/-).A. OLETF (-/-); OLETF rat fed on tap water and treated with saline, B. OLETF (-/+); OLETF rat fed on tap water and
treated with G-CSF, C. OLETF (+/-); OLETF rat fed on sucrose water and treated with saline, D. OLETF (+/+); OLETF rat fed on sucrose water and
treated with G-CSF.
Lim et al. Cardiovascular Diabetology 2011, 10:92
http://www.cardiab.com/content/10/1/92
Page 8 of 10
In the present study, we found in the immunohisto-
chemical findings that G-CSF inhibited presentation of
TGF-b and progression of fibrosis. Such findings can
enhance our understanding of the effects of G-CSF on
myocardium, though further investigation is required to
establish the exact mechanism of the protective effect of
G-CSF in diabetic CMP.
• Limitation of the study
This study has two main limitations. First the number of
subjects was small. Second, data on optimal G-CSF regi-
mens such as dose, timing, frequency and duration are
limited. In order to overcome these limitations, a precli-
nical study of the effects of G-CSF on diabetic CMP
should be carried out with a larger number of subjects,
and the G-CSF regimen should be optimized. Elucidat-
ing the major mechanism underlying the improvement
of heart function by G-CSF treatment will require much
more investigation.
• Clinical and research implications of the findings
In the clinical setting, patients with diabetic CMP have
increased in number, and moreover end-stage dilated
CMP is the reality. Despite the increasing burden of dia-
betic CMP, the development of new treatment modal-
ities has received little attention, and treatment is still
largely based on conventional approaches such as strict
glycemic control, management of symptoms and the use
of renin-angiotensin-aldosterone system inhibitors and
beta blockers [9-12]. In this study, we demonstrated that
G-CSF has beneficial functional and histological effects
on diabetic CMP. Further studies on the mechanism
and for clinical implications would be desirable.
Conclusions
In this study we evaluated the functional and histological
effect of G-CSF on relatively early diabetic CMP. We
found that diastolic dysfunction was minimal or comple-
tely recovered in OLETF rats treated with G-CSF. The
beneficial effects of G-CSF were shown in the histologic
findings as well. Perivascular and interstitial fibrosis pro-
gressed more slowly or even showed improvement in G-
CSF treated OLETF rat groups. Also, the extent of TGF-b
immunoreactivity in the interstitial and perivascular tissue
was significantly decreased in G-CSF treated OLETF rat
groups. EM studies revealed decreased collagen deposition
and lesser number of abnormal mitochondria, damaged
myofilaments and intracellular junctions were also noted
in G-CSF treated OLETF rats. Our results indicate that
the protective effects of G-CSF are seen diabetic. There-
fore, G-CSF can ameliorate cardiac diastolic dysfunction
and morphological damage, especially fibrosis of the myo-
cardium, in OLETF rats with diabetic CMP. The present
study provides the first evidence of the beneficial effects of
G-CSF on diabetic CMP in OLETF rats.
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Figure 5 The ultrastructure of saline-treated sucrose contained water fed OLETF rat (OLETF (+/-)) myocardium displays deposition of
collagen fibers in pericapillary region and swelling of mitochondria in cardiac cells, whereas G-CSF treat rats (OLETF (+/+)) reveals
absence of collagen deposition and relatively decreased number of abnormal mitochondria. Note the disruption or distortion of cristae
network of the enlarged mitochondria in non-treated sucrose fed group (inset). N: nucleus, R: red blood cell, M: mitochondria, arrow: collagen fiber.
A. OLETF (+/-); OLETF rat fed on sucrose water and treated with saline, B. OLETF (+/+); OLETF rat fed on sucrose water and treated with G-CSF.
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